Pharmakokinetik von Testogel^®

Gooren, L., & Bunck, M. (2004). Androgen replacement therapy: present and future. Drugs , 64 (17), pp. 1861-91.

Wang C, Berman N, Longstreth JA, et al. (2000). Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab, 85(3),pp. 964-969.

Miller J., Britto M., Fitzpatrick S., et al. (2011). Pharmacokinetics and relative bioavailability of absorbed testosterone after administration of a 1.62% testosterone gel to different application sites in men with hypogonadism. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 17(4), pp. 574-583.

Swerdloff RS, Wang C., Cunningham G., et al. (2000). Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab, 85(12), pp. 4500-4510.

Wang, C., et al. (2004, May). Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab, 89 (5), pp. 2085-98.

Snyder PJ (2006). Androgens. In: Brunton LL, Lazo JS, Parker KL. Goodman and Gilman´s the pharmacological basis of therapeutics, 11 ed. New York: McGraw-Hill; 2006.

Kaufman JM, T’Sjoen G., Vermeulen A. (2004). Androgens in male senescence. In: Nieschlag E., Behre HM. Testosterone – action, deficiency, substitution. Cambridge: Cambridge University Press; 2004.

Liu ZH, Kanjo Y, Mizutani S (2009). Urinary excretion rates of natural estrogens and androgens from humans, and their occurrence and fate in the environment: a review. The Science of the total environment, 407(18),pp. 4975-4985.